All In Biotech

Drug Trial Radar · NCT00244244

A Multicenter, Dose Ranging Safety and Pharmacokinetics Study of Arimoclomol in ALS

A Multicenter, Dose Ranging Safety and Pharmacokinetics Study of Arimoclomol in Amyotrophic Lateral Sclerosis (ALS)

Last checked: Nov 19, 2026Latest source record: Feb 9, 2012 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

80

Actual

Start

Oct 2005

Primary completion

Jan 2007

Study completion Jan 2007

Sponsor

Lead sponsor
CytRxIndustry
Sponsor type
Industry
First posted
Oct 26, 2005

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Single group
Masking
Double
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary purpose of this study is to evaluate the safety and tolerability of arimoclomol in ALS patients following 90 days of dosing. In addition, the amount of arimoclomol in blood and cerebrospinal fluid will be measured.

Conditions

  • Amyotrophic Lateral Sclerosis (ALS)

Interventions

  • arimoclomolDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Safety

Locations

10 sites in 1 country. Site status is shown where the registry gives one.

  • University of California, Irvine Medical Center

    Irvine, California

  • University of Miami School of Medicine

    Miami, Florida

  • University of Kansas Medical Center

    Kansas City, Kansas

  • Massachusetts General Hospital

    Boston, Massachusetts

  • Hennepin Faculty Associates/Berman Center

    Minneapolis, Minnesota

  • SUNY Upstate Medical University

    Syracuse, New York

  • Duke University

    Durham, North Carolina

  • Penn State Milton S. Hershey Medical Center

    Hershey, Pennsylvania

  • Drexel University College of Medicine

    Philadelphia, Pennsylvania

  • University of Texas Health Science Center at San Antonio

    San Antonio, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.